Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024.
Poster presentation:
AACR 2024
https://www.aacr.org/meeting/aacr-annual-meeting-2024/
Location: San Diego Convention Center, San Diego
Date: April 5-10, 2024
Details on the poster presentation are as follows:
Abstract title: TCR-gated control of costimulatory switch protein (CSP) activation in rTCR-T cells expressing PD1-41BB
Maja Buerdek, Petra U. Prinz, Kathrin Mutze, Andrea Coluccio, Stefanie Tippmer, Miriam Bosch, Giulia Longinotti, Mario Catarinella, Kathrin Davari, Christiane Geiger, Barbara Loesch, Kristy Crame,
Dolores J. Schendel.
Session details: PO.IM01.13 - Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T, Sunday, April 7, 1:30 PM - 5:00 PM local time
The work to be presented shows that recombinant T cell receptor engineered T cells (rTCR-T cells), when armored and enhanced by the PD1-41BB CSP, exhibit superior TCR-T cell functionality and safety as well as a favorable safety profile, revealing the strong potential for improving treatment of cancer patients suffering from advanced solid tumor malignancies.
The abstract for this research has been published online at https://www.abstractsonline.com/pp8/#!/20272/presentation/6084 and the poster will be available online after the conference at https://medigene.com/science/abstracts/.
Lesen Sie auch
The Company is planning a first-in-human trial for MDG1015, a TCR-T therapy incorporating the CSP in gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024. MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by the PD1-41BB CSP.
Oral presentation:
ELRIG-Forum 2024
https://www.elrig.de/index.php/elrig-foren/elrig-forum-2024
Location: Darmstadtium Convention Centre, Darmstadt
Date and time: March 7, 2024, 11:10 – 11:30am local time
Presenter: Dr. Barbara Lösch, Head, Technology & Innovation
Title: Evolution by Innovation: Connecting the Dots of TCR-T Therapies
Dr. Lösch will provide an overview on the Company’s proprietary End-to-End (E2E) Platform and highlight various tools within the E2E Platform that can enhance TCR-T cell functionality, safety and efficacy for generation of best-in-class, differentiated TCR-T therapies.